Fluoropharma Financial Statements From 2010 to 2025
| FPMI Stock | USD 0.0001 0.00 0.00% |
Check Fluoropharma Medical financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Fluoropharma Medical's main balance sheet or income statement drivers, such as , as well as many indicators such as . Fluoropharma financial statements analysis is a perfect complement when working with Fluoropharma Medical Valuation or Volatility modules.
Fluoropharma |
Fluoropharma Medical Company Shares Outstanding Analysis
Fluoropharma Medical's Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Current Fluoropharma Medical Shares Outstanding | 34.26 M |
Most of Fluoropharma Medical's fundamental indicators, such as Shares Outstanding, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Fluoropharma Medical is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
| Competition |
Based on the latest financial disclosure, Fluoropharma Medical has 34.26 M of shares currently outstending. This is 81.02% lower than that of the Biotechnology sector and 67.94% lower than that of the Health Care industry. The shares outstanding for all United States stocks is 94.01% higher than that of the company.
Fluoropharma Medical Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Fluoropharma Medical's current stock value. Our valuation model uses many indicators to compare Fluoropharma Medical value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Fluoropharma Medical competition to find correlations between indicators driving Fluoropharma Medical's intrinsic value. More Info.Fluoropharma Medical is rated below average in return on asset category among its peers. It is rated below average in current valuation category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value Fluoropharma Medical by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Fluoropharma Medical's Pink Sheet. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.About Fluoropharma Medical Financial Statements
Investors use fundamental indicators, such as Fluoropharma Medical's revenue or net income, to determine how well the company is positioned to perform in the future. Although Fluoropharma Medical's investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
FluoroPharma Medical, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of molecular imaging pharmaceuticals with initial applications in the area of cardiology in the United States. FluoroPharma Medical, Inc. was founded in 2003 and is headquartered in Montclair, New Jersey. Fluoropharma Medical operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 4 people.
Currently Active Assets on Macroaxis
Other Information on Investing in Fluoropharma Pink Sheet
Fluoropharma Medical financial ratios help investors to determine whether Fluoropharma Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Fluoropharma with respect to the benefits of owning Fluoropharma Medical security.